Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (271-280 of 362) with videos related to

Pageof 37
Sort By:
Clinical Lung Cancer|April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyEdward B Garon, Byoung Chul Cho, Alexander Luft, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyCharles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Clinical Lung Cancer|March 29, 2021
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)Edward B Garon, Byoung Chul Cho, Niels Reinmuth, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
JTO Clinical and Research Reports|November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCHye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Future Oncology (London, England)|April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Pageof 37

Showing results (271-280 of 362) with videos related to

Sort By:
Pageof 37
Clinical Lung Cancer|April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyEdward B Garon, Byoung Chul Cho, Alexander Luft, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyCharles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Clinical Lung Cancer|March 29, 2021
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)Edward B Garon, Byoung Chul Cho, Niels Reinmuth, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
JTO Clinical and Research Reports|November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCHye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Future Oncology (London, England)|April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Pageof 37